[ad_1] MELBOURNE, Australia, Nov. 12, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in the Company’s Phase III…
Tag: ProstACT
ProstACT SELECT Study of TLX591 Interim Readout: Positive Results Confirm Safety and Tolerability
[ad_1] The study has achieved its primary objectives, confirming the safety and tolerability profile of TLX591 administered in two doses, two weeks apart in combination with standard of care (SoC)…